Our mission is to spearhead humanity’s process of enhancing itself in an act of its own creation by focusing on mental health & longevity, fueled by AI. We enable people to live longer, healthier and happier lives.
Our name is derived from ATAI, the ancient African goddess of creation. Homo Sapiens has started to emerge in Africa approximately 300,000 years ago and the development is now coming full circle. We are right at the tipping point for the next evolutionary step: Modern science combined with state-of-the-art technology like artificial intelligence and big data solutions is about to dramatically extend our lifespan and enhance our physical and mental abilities.
We aim to become the leading biotech company globally in this final frontier for humanity as we know it by developing and acquiring promising therapeutics focusing on longevity and mental wellbeing.
We have a special passion for psychedelics. Our holding COMPASS Pathways is developing a psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression. Several academic studies – the first dating back to the 1950s – have suggested that psilocybin therapy provides immediate and sustained reductions in depression and other illnesses. COMPASS has just started its phase IIb trial in the US, Canada and Europe, which is the largest trial ever done with a psychedelic substance.
ATAI Life Sciences AG has been founded by Apeiron Investment Group Ltd, the family office of Christian Angermayer.